First, the team assumed that immune checkpoint inhibitor therapy targeted local tumor microenvironment, and CD8+ TRM cells might be crucial to its therapeutic effect on cancer; The phenotypic characteristics and cytokine requirements for the production and maintenance of different intratumoral CD8+ T cell subsets in cancer were established. The gene discussed is CD8A; the disease is cancer.